Ph III Study of Infant via Maternal Immunization Vaccine for RSV Reaches Milestone

Novavax, Inc. (Nasdaq:NVAX) announced on 5/7/18 it has reached a significant milestone in the Prepare Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Enrollment has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F Vaccine.